Acyclovir Articles
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Do Wellcome Results Justify Higher Bid
6 February 1995
Valtrex Launched In Its First Markets
6 February 1995
Glaxo Wellcome: Consolidatory But No Panacea
30 January 1995
Glaxo Bids L8.9 Billion To Take Over Wellcome
30 January 1995
Factors Affecting Pricing And Volume In Europe
30 January 1995
European STOCK COMMENT
23 January 1995
FDA C'tee Gives Thumbs Down For OTC Zovirax
23 January 1995
European Stock Comment
16 January 1995
Wellcome, Hoechst Copromotion Deal
2 January 1995
Burroughs Wellcome Outlook Reviewed
19 December 1994
Zovirax OTC Change In Generic Name
31 October 1994
EUROPEAN STOCK COMMENT
31 October 1994
UK Code Of Conduct Quarterly Review
17 October 1994
New Data On Antiherpetics Presented At ICAAC
17 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
Wellcome: Gloves Off In Antiviral Battle
5 September 1994
US Launch For SB's Famvir
8 August 1994
Four-Month Results At Wellcome As Expected
25 July 1994
Retrovir/Zovirax May Prolong HIV Survival
25 July 1994
Wellcome Files First PLAs for Valaciclovir
18 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
ACICLOVIR NOT ASSOCIATED WITH RESISTANCE
11 July 1994
US APPROVAL FOR SB'S FAMCICLOVIR
11 July 1994
HEAD OF UK HERPES ASSOCIATION COMMITTED FOR TRIAL
20 June 1994
BOOTS LOOKING MORE TO THE OTC SECTOR
13 June 1994
WARNER WELLCOME JV SETS SIGHTS ON TOP SPOT
6 June 1994
EUROPEAN STOCK COMMENT
30 May 1994
RESISTANCE BARRIER TO OTC ZOVIRAX IN USA?
30 May 1994
EUROPEAN STOCK COMMENT
16 May 1994
SWITCHING TO OTC STATUS IN EUROPE
2 May 1994
RX-TO-OTC: MAKING THE DECISION TO SWITCH
18 April 1994
UK OTC MARKET SAW 13.5% VALUE GROWTH IN 1993
11 April 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
EUROPEAN STOCK COMMENT
4 April 1994
MORE ON NETIVUDINE WITHDRAWAL
4 April 1994
PAN-EUROPEAN BRANDING IN THE OTC MARKET
4 April 1994
WELLCOME'S SHARE PRICE WOES
4 April 1994
EUROPEAN STOCK COMMENT
28 March 1994
INTERIM PRETAX UP 12% AT WELLCOME
28 March 1994
UK CONSUMERS BUYING MORE OTC MEDICINES
28 March 1994
PUBLIC HEARING FOR ZOVIRAX SWITCH PLANNED
21 March 1994
WELLCOME FACES PATENT CHALLENGE
7 March 1994
NET PROFITS LEAP AT SUMITOMO PHARMA
7 March 1994
WELLCOME BOTTOMING OUT; IMPROVEMENT AHEAD
28 February 1994
PRYOR REPORT SLAMS INDUSTRY OVER PRICES
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
EUROPEAN STOCK COMMENT
24 January 1994
1ST FAMVIR LAUNCH SPARKS WELLCOME PRICE CUT
24 January 1994
WELLCOME "TOO FOCUSED" FOR INDEPENDENCE
24 January 1994
TEVA RECEIVES FAVOURABLE RULING
10 January 1994
TRUST TO RETAIN WELLCOME SHARES
10 January 1994
ZOVIRAX ANOUNCEMENT
10 January 1994
EFFECTS OF UK MOVES TO CURB NHS DRUG SPENDING
10 January 1994
ACICLOVIR RESISTANCE
20 December 1993
EUROPEAN STOCK COMMENT
20 December 1993
FAMCICLOVIR APPROVED IN ITS FIRST MARKET
20 December 1993
IS THE WORST OVER FOR DRUG STOCKS?
20 December 1993
UK GOVT URGES OTC USE, ECONOMIC EVALUATION
6 December 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
ZOVIRAX PERFORMANCE: A WORRY FOR WELLCOME?
8 November 1993
WELLCOME RESULTS AS EXPECTED BUT US SLOWER
1 November 1993
PHARMACEUTICAL PRICING IN EUROPE
1 November 1993
ANTIVIRAL CLASH LOOMS AS ICAAC DATA PRESENTED
25 October 1993
EUROPEAN STOCK COMMENT
25 October 1993
BIOCINE'S VACCINE PIPELINE
25 October 1993
USEVIR PULLED AS DEATHS FOLLOW LAUNCH
25 October 1993
SHAMAN PHARMA ON THE WARPATH
25 October 1993
EUROPEAN STOCK COMMENT
11 October 1993
CLINICAL DATA PRESENTED ON FAMCICLOVIR
4 October 1993
EUROPEAN STOCK COMMENT
4 October 1993
ACICLOVIR INDICATED FOR CHICKENPOX IN UK
27 September 1993
ADAPTING TO A CHANGING DRUG IND ENVIRONMENT
20 September 1993
EUROPEAN STOCK COMMENT
6 September 1993
CHANGES TO UK DRUG STATUS
16 August 1993
ZOVIRAX MAY BE PRESCRIBED FOR CHICKENPOX
2 August 1993
WARNER-LAMBERT OTC DEALS ON ZOVIRAX, ZANTAC
2 August 1993
FAMCICLOVIR NEARING MARKET
26 July 1993
DELISTING AND OTC SALES IN DENMARK
26 July 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
WELLCOME NOT JUST AN ANTIVIRAL COMPANY?
19 July 1993
ZOVIRAX TO PREVENT GENITAL HERPES
12 July 1993
VARIED VIEWS ON WELLCOME'S PROFIT OUTLOOK
5 July 1993
EUROPEAN STOCK COMMENT
28 June 1993
EUROPEAN STOCK COMMENT
31 May 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
FAMICICLOVIR AS EFFECTIVE AS ZOVIRAX
24 May 1993
ZOVIRAX GAINS OTC INDICATION
24 May 1993
WELLCOME REFOCUSING R&D EFFORTS
10 May 1993
ACICLOVIR VERSUS PENCICLOVIR
10 May 1993
ZOVIRAX RESISTANT PROBLEMS
3 May 1993
WELLCOME BUILDS OTC PRESENCE
26 April 1993
LONDON STOCK COMMENT
12 April 1993
ABPI SEES 14 BREACHES OF PRACTICE CODE
12 April 1993
FRENCH HERPES DEAL FOR WELLCOME
5 April 1993
POOR MARKET REACTION TO WELLCOME RESULTS
5 April 1993
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
